Vaccine development against SARS-CoV-2 has been fierce due to the devastating COVID-19 pandemic and has included all potential approaches for providing the global community with safe and efficient vaccine candidates in the shortest possible timeframe. Viral vectors have played a central role especially using adenovirus-based vectors. Additionally, other viral vectors based on vaccinia viruses, measles viruses, rhabdoviruses, influenza viruses and lentiviruses have been subjected to vaccine development. Self-amplifying RNA virus vectors have been utilized for lipid nanoparticle-based delivery of RNA as COVID-19 vaccines. Several adenovirus-based vaccine candidates have elicited strong immune responses in immunized animals and protection against challenges in mice and primates has been achieved. Moreover, adenovirus-based vaccine candidates have been subjected to phase I to III clinical trials. Recently, the simian adenovirus-based ChAdOx1 vector expressing the SARS-CoV-2 S spike protein was approved for use in humans in the UK.
【저자키워드】 COVID-19, SARS-CoV-2, Vaccines, clinical trials, Adenovirus, preclinical immunization, approved vaccine, breath, 【초록키워드】 viruses, Viral vector, Vaccine development, Phase I, Influenza, COVID-19 pandemic, Human, Influenza virus, Spike protein, RNA, COVID-19 vaccines, Viral, mice, lentivirus, vector, immune responses, Community, viral vectors, vaccine candidate, influenza viruses, RNA virus, ChAdOx1, Safe, lentiviruses, primates, vectors, strong immune response, approach, immunized, approved, expressing, elicited, adenovirus-based, the SARS-CoV-2, 【제목키워드】 vector, development,